Anupam Rasayan India Ltd (ANURAS) Fair Value & Analysis
Basic Materials · IN · Market cap ₹145B
Fair value as of: Jun 29, 2026
Analysis
Anupam Rasayan India Ltd (ANURAS) currently trades at ₹1,275, while our model-based Fair Value estimate is ₹254.03 — implying the stock looks roughly 80.1% overvalued today. We read business quality at 82/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Anupam Rasayan India Ltd engages in the custom synthesis and manufacturing of specialty chemicals in India, Europe, Japan, Singapore, China, North America, and internationally. It operates through two segments: Life Science related Specialty Chemicals and Other Specialty Chemicals. The company offers life science related specialty chemicals, such as agro intermediates and agro active ingredients for the agrochemicals industry; anti-bacterial and ultraviolet protection intermediates and ingredients for the personal care industry; and intermediates and key starting materials for active pharmaceutical ingredients. It provides other specialty chemicals used in various end-user segments, including specialty pigments, specialty dyes, and polymer additives. The company was incorporated in 1984 and is headquartered in Surat, India.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Anupam Rasayan India Ltd (ANURAS) undervalued?
What is the fair value of ANURAS?
What is the quality score of ANURAS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.